Pseudobulbar Affect (Pba) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Pseudobulbar Affect (PBA), also known as emotional lability, pathological crying and laughing, or pseudobulbar cry, is a neurological disorder characterized by involuntary, inappropriate, and often uncontrollable episodes of crying or laughing that are disproportionate to or unrelated to the patient's emotional state [1]. These emotional outbursts can be triggered by minor stimuli or may occur spontaneously, causing significant distress and social embarrassment for affected individuals.
PBA results from damage to the neural pathways that regulate emotional expression. Unlike normal emotional responses, PBA episodes are not connected to the patient's true feelings and often occur in inappropriate contexts. For example, a patient may burst into laughter when hearing sad news or cry uncontrollably during a happy occasion [2].
The condition is estimated to affect approximately 1-2 million people in the United States, though it is likely underdiagnosed due to lack of awareness among healthcare providers and patients alike [3]. PBA can significantly impact quality of life, interfering with social interactions, relationships, and daily activities.
PBA results from disruption of the corticobulbar tract, which connects the cerebral cortex to the brainstem nuclei responsible for emotional expression. This pathway helps regulate the appropriate expression of emotions based on contextual social cues [4]. When this circuitry is damaged, there is a loss of cortical inhibition over brainstem emotional response centers, leading to uncontrolled emotional outbursts.
The condition involves dysfunction in several brain regions:
Research suggests that PBA involves dysregulation of neurotransmitter systems, particularly:
The degeneration or injury to specific neuron populations leads to imbalance between excitatory and inhibitory signals, resulting in inappropriate emotional expression [5].
PBA is most commonly associated with the following neurological conditions:
Amyotrophic Lateral Sclerosis (ALS): Up to 50% of ALS patients experience PBA symptoms, making it one of the most common associated conditions [6]. The degeneration of upper motor neurons in the corticobulbar tract disrupts emotional regulation pathways.
Frontotemporal Dementia (FTD): PBA occurs in approximately 10-15% of FTD patients, often presenting early in the disease course [7]. The degeneration of frontal and temporal brain regions disrupts emotional control mechanisms.
Alzheimer's Disease: While less common than in ALS or FTD, PBA can occur in 5-10% of Alzheimer's patients, particularly in moderate to advanced stages [8].
Parkinson's Disease: Some Parkinson's patients experience PBA, though it is less well-characterized than in other movement disorders [9].
Multiple System Atrophy (MSA): PBA has been reported in MSA patients, often accompanying other autonomic and motor symptoms.
Traumatic brain injury (TBI), especially when involving diffuse axonal injury or damage to frontal lobes, can result in PBA. Estimates suggest 5-10% of TBI survivors develop PBA [11].
Diagnosis of PBA is primarily clinical, based on:
The Pathological Laughter and Crying Scale (PLACS) is a validated tool used to assess PBA severity [12]. Healthcare providers also use the:
It is essential to differentiate PBA from:
The only FDA-approved medication specifically for PBA is dextromethorphan/quinidine [13]:
Off-label treatments include:
These agents modulate serotonin and norepinephrine pathways, helping stabilize emotional regulation [14].
PBA significantly affects multiple domains:
Current research focuses on:
The study of Pseudobulbar Affect (Pba) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Schiffer R, Pope LE. Review of pseudobulbar affect including a novel and potential therapy. J Neuropsychiatry Clin Neurosci. 2005;17(4):447-454. DOI:10.1176/jnp.17.4.447
[2] Cummings JL, Arciniegas DB, Brooks BR, et al. Defining and diagnosing involuntary emotional expression disorder. CNS Spectr. 2006;11(9):1-13. DOI:10.1017/s1092852900024301
[3] Brooks BR, Crumpacker D, Fellus J, Cohen R, Kaye RE. Pseudobulbar affect: an under-recognized and under-treated disorder. J Neurosci Nurs. 2008;40(5):265-271.
[4] Parvizi J, Anderson SW, Martin CO, Damasio H, Hanna GR, Damasio AR. Pathological laughter and crying: a link to the cerebellum. Brain. 2001;124(Pt 9):1708-1721. DOI:10.1093/brain/124.9.1708
[5] Lauterbach EC, Cummings JL, Kuppuswamy PS. Toward a more precise, clinically-informed pathophysiology of pseudobulbar affect. Neurol Sci. 2013;34(11):1873-1881. DOI:10.1007/s10072-013-1390-0
[6] Thakore NJ, Pioro EP. Laughter, crying and sadness in ALS. J Neurol Neurosurg Psychiatry. 2017;88(10):825-831. DOI:10.1136/jnnp-2017-315641
[7] Mendez MF, McMurtray A, Licht E, Saul RE, Thai LJ. The frequency of aggressive behaviors in behavioral variant frontotemporal dementia with and without psychosis. J Geriatr Psychiatry Neurol. 2006;19(1):59-64. DOI:10.1177/0891988706286205
[8] Starkstein SE, Migliorelli R, Tesón A, et al. Prevalence and clinical correlates of pathological affect in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1995;59(1):55-60. DOI:10.1136/jnnp.59.1.55
[9] Nadeau SE. Pseudobulbar affect. Neurology. 2002;59(10):1643-1644.
[10] House A, Dennis M, Molyneux A, Warlow C, Hawton K. Emotionalism after stroke. BMJ. 1989;298(6669):307-309. DOI:10.1136/bmj.298.6669.307
[11] Zeilig G, Ditunno JF, Goetz LL, et al. The diagnostic challenge of pseudobulbar affect in traumatic brain injury. Brain Inj. 2019;33(8):1104-1111. DOI:10.1080/02699052.2019.1606444
[12] Robinson RG, Parikh RM, Lipsey JR, Starkstein SE, Price TR. Pathological laughter and crying: development of a co-morbidity scale. J Neuropsychiatry Clin Neurosci. 1993;5(3):276-281. DOI:10.1176/jnp.5.3.276
[13] Pioro EP, Brooks BR, Crump J, et al. Dextromethorphan/quinidine pseudobulbar affect. CNS Drugs. 2014;28(1):33-42. DOI:10.1007/s40263-013-0128-0
[14] Drayton SJ, Davis VA, Clayton MM. Use of sertraline for pseudobulbar affect. J Clin Psychopharmacol. 2002;22(4):433-434. DOI:10.1097/00004714-200208000-00017